VANCOUVER, BC--(MARKET WIRE)--Jul 10, 2007 -- Upstream Biosciences Inc. (OTC BB:UPBS.OB - News), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, today announced that it has retained Genpathway, Inc. to conduct analysis using its highly sensitive chromatin immunoprecipitation assays. The analysis is intended to provide critical information for the next phase of Upstream’s program to validate its first two cancer biomarkers and drug response assay. Genpathway will apply its assays to help elucidate critical parameters involving specific gene transcription factors and pathways.
